Considering a Bone Marrow Transplant for JAGN1

For many children with JAGN1 severe congenital neutropenia (SCN), daily injections of G-CSF are enough to manage the condition. However, for some, the “factory” in the bone marrow simply does not respond well enough to medicine. In these cases, a hematopoietic stem cell transplant (HSCT)—also known as a bone marrow transplant—may be considered. It is currently the only known potential correction for the blood-related symptoms of JAGN1 deficiency ^[1][2].

When Is a Transplant Recommended?

A transplant is a major medical procedure with significant risks, so the decision is highly individualized. It is usually reserved for specific situations where the benefits of a “new” immune system outweigh the dangers of the procedure itself ^[3]. Doctors typically consider HSCT for JAGN1 patients in the following scenarios:

• G-CSF Refractoriness or Inadequate Response: This means the bone marrow does not produce enough neutrophils, or the patient continues to suffer from repeated bouts of severe infections despite optimized G-CSF, indicating the therapy is not providing a “functional” response ^[4][2][5].
• The “High-Dose” Threshold: While there is no single universal rule, in some major clinical registries (like the French ELANE registry), requiring more than 15 micrograms per kilogram (µg/kg) per day has been used as a threshold to evaluate patients for transplant eligibility, due to the risks of prolonged high-dose dependence ^[6][4].
• MDS or AML: If regular bone marrow monitoring shows signs of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML)—conditions where the bone marrow cells begin to grow abnormally or become cancerous—a specialized oncology team will guide the management plan, which often involves a transplant ^[4][7].

Balancing the Transplant Risks

While a successful transplant can correct the neutropenia, it carries severe, life-threatening risks. These risks include severe infection during the recovery period, regimen-related organ toxicity, infertility, chronic Graft-versus-Host Disease (GvHD) (where donor cells attack the patient’s body), graft failure, secondary malignancy, and prolonged hospitalization or death ^[1][3]. Furthermore, HSCT typically corrects only the blood defect; it does not reverse established dental problems or syndromic features like short stature ^[4][8].

JAGN1-SCN also has a very specific challenge called autologous reconstitution ^[4].

Autologous reconstitution happens when the patient’s own JAGN1-deficient stem cells—the ones that survived the pre-transplant chemotherapy—begin to grow back and push out the healthy donor cells ^[4]. If this happens, the neutropenia and the risk of infection return. In the largest study of JAGN1 patients to date, a small number of children experienced this and required a second transplant to successfully replace the “broken” immune system ^[4].

The Transplant Process

The goal of HSCT is to replace your child’s JAGN1-deficient stem cells with healthy ones from a donor. This involves several stages:

1. Conditioning: Your child receives chemotherapy (and sometimes radiation) to clear out their own bone marrow and make room for the new cells ^[1].
2. Infusion: The donor’s stem cells are given through an IV, similar to a blood transfusion.
3. Engraftment: The family waits several weeks for the new cells to travel to the bone marrow and begin producing healthy white blood cells, red blood cells, and platelets. This requires center-specific hospitalization and infection precautions ^[3].

Making the Decision

Deciding to pursue a transplant is a deeply personal and complex choice. It is essential to have these conversations at a specialized pediatric transplant center that has experience with rare genetic immune deficiencies. They can help you weigh your child’s specific infection history, the risks of the conditioning regimen, and donor options against the potential for a permanent hematologic correction ^[2].